SEARCH

SEARCH BY CITATION

References

  • 1.
    Willis P, Voeltz MD. Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;104(5 suppl):34C38C.
  • 2.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673682.
  • 3.
    Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;1045 suppl:9C15C.
  • 4.
    Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:20452048.
  • 5.
    Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:22182230.
  • 6.
    Stone GW, White HD, Ohman EM, et al; Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial Investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Lancet. 2007;369:907919.
  • 7.
    Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142154.
  • 8.
    Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol. 2007;100:13641369.
  • 9.
    Valente S, Lazzeri C, Chiostri M, et al. NT-proBNP on admission for early risk stratification in STEMI patients submitted to PCI with extension of STEMI and inflammatory markers. Int J Cardiol. 2009;132:8489.
  • 10.
    Valente S, Lazzeri C, Salvadori C, et al. Effectiveness and safety of routine primary angioplasty in patients aged > or = 85 years with acute myocardial infarction. Circ J. 2008;72:6770.
  • 11.
    Valente S, Lazzeri C, Chiostri M, et al. Time of onset and outcome of cardiogenic shock in acute coronary syndromes. J Cardiovasc Med (Hagerstown). 2008;9:12351240.
  • 12.
    Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined [published correction appears in J Am Coll Cardiol. 2001;37:973]. J Am Coll Cardiol. 2000;36:959969.
  • 13.
    Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:15031516.
  • 14.
    National Kidney Foundation. K/DOQI: clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1): S1S266.
  • 15.
    Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809816.
  • 16.
    Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:11931204.
  • 17.
    Bassand JP. Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart. 2008;94:661666.
  • 18.
    Nikolsky E, Mehran R, Dangs G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:19361945.
  • 19.
    Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:25562566.
  • 20.
    Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance and paradigms for reducing risk. Clin Cardiol. 2007;30(10 suppl 2):II24II34.
  • 21.
    Bassand JP. Acute coronary syndromes and percutaneous coronary interventions. Hamostaseologie. 2009;29 381387.
  • 22.
    Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:13621368.
  • 23.
    Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24: 18151823.
  • 24.
    Siudak Z, Zawislak B, Dziewierz A, et al. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry. Coron Artery Dis. 2010;21: 292297.